Published in TB and Outbreaks Week, November 13th, 2001
Dr. Latham comes to PanTherix from Sanofi-Synthelabo, where he was head of cardiovascular chemistry from 1996. At Sanofi-Synthelabo he had responsibility for development of the company's overall cardiovascular drug development strategy, managed a number of significant research programs and established new approaches to lead generation and drug design. Dr. Latham also facilitated important corporate collaborations...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.